Systems and Methods for Gut-Targeted GABA-A Positive Allosteric Modulation Using Thiolane-Purine Scaffold Compounds for Liver-Safe Relaxation

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This work discloses a computational screening pipeline and resulting compound candidates for a novel liver-safe relaxation mechanism: gut-targeted positive allosteric modulation of GABA-A receptors in the enteric nervous system, without requiring systemic absorption or CNS penetration. The invention exploits the gut-brain vagal signaling axis — activation of enteric GABA-A receptors reduces vagal afferent firing and modulates central autonomic tone, producing relaxation without hepatotoxic metabolites or CNS drug scheduling risk. Lead compounds belong to the thiolane-purine scaffold class and were identified by deliberately inverting standard ADMET drug-likeness criteria to select for poor BBB penetration, low oral bioavailability, GI luminal stability, and absence of CYP2E1 metabolism. Top candidates include CHEMBL200732 (pChEMBL 9.80, priority score 1376), namodenoson (pChEMBL 9.37, priority score 1324), and CHEMBL387921 (pChEMBL 10.99, priority score 1319), all confirmed patent-clear for the disclosed use via USPTO and Google Patents search. The screening pipeline is archived at github.com/glenritschel/gut-gaba-screen. This document is the provisional patent specification filed with the USPTO on March 22, 2026 (Application No. 64/013,074).

Fields of Study & Subjects

Computational Drug Discovery Methods Neuroscience and Neuropharmacology Research Gastrointestinal motility and disorders

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
22 March 2026
Language
EN